Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2012


Site Feasibility and Study Start Up

17 Oct 2012 - 18 Oct 2012 - London, UK



Bookmark and Share


The majority of clinical trials overrun due to poor site feasibility and less than 50% of sites meet study enrolment goals – discover how to avoid this in your own study start up by attending Informa’s Site Feasibility and Study Start Up conference this October.

With 14+ industry led case studies and 18+ site feasibility and study start up experts on hand to answer your questions, this event is not to be missed.

Our 2012 expert speaker panel includes:

Vibeke Breinholt, Director Clinical Operations, Ferring Pharmaceuticals, Denmark

Holly Edgar, Associate Director, Late Phase Clinical Development & Operations Astellas Pharma Europe, UK

John Needham, (Former Senior Director, Recruitment Strategy, Johnson & Johnson Pharmaceutical Research and Development (JJPRD), USA)

Dr Rajeev Chavda, Medical Director, Pierre-Fabre Group, India

Get your questions answered by leading industry experts in our interactive round table discussions. Visit the event website for the full agenda and speaker line up.



Further information
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!